DrugForm-TAS: Target-Agnostic Selectivity as Proteome-wide Binding Propensity Estimation
Computational and Structural Biotechnology Journal · 01.03.2026 · 35 (1)
DOI: 10.34133/csbj.0034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 18.05.2026. Verfasst von Anna Tashchilova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agenc…. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Assessing the selectivity of binding a small molecule with proteins remains a fundamental yet unresolved challenge in computational drug discovery. Conventional strategies for estimating ligand selectivity depend on exhaustive cross-prediction of binding affinities across thousands of potential off-target proteins—an approach that is computationally prohibitive for large-scale virtual screening or de novo molecular design. Here, we present DrugForm-TAS (Target-Agnostic Selectivity), the first model capable of directly predicting an unconditional, quantitative measure of small-molecule proteome-wide binding propensity without requiring any prior knowledge of target proteins or affinity thresholds. Built upon our previously developed DrugForm-DTA model, which enables affinity prediction for arbitrary protein targets, and trained on a thoroughly curated dataset derived from BindingDB, DrugForm-TAS employs a lightweight transformer-like neural network that operates solely on a ligand’s SMILES representation. The model acts as a fast pre-screening filter that can greatly reduce the candidate set, as evidenced by the correlation between its predictions and experimental observations. By eliminating the need for target-specific computations, DrugForm-TAS enables target-agnostic nonspecificity profiling. When combined with drug–target affinity calculation, it provides a novel tool for fast pre-screening selectivity estimation in early-stage drug design.
Autor:innen und Institutionen
- Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency (Centre for Strategic Planning of FMBA of Russia), Moscow 119121, Ru…
- The Federal Medical Biological Agency (FMBA of Russia), Moscow 123182, Russia.
ORCID-Profile: Anna Tashchilova, Ivan Khokhlov, Nickolay Bugaev-Makarovskiy, Dmitry Svetlichnyy
Zitieren
APA
Tashchilova, A., Khokhlov, I., Seikin, A., Bugaev-Makarovskiy, N., Glushkova, O., Yudin, V., Keskinov, A., Yudin, S., Svetlichnyy, D., & Skvortsova, V. (2026). DrugForm-TAS: Target-Agnostic Selectivity as Proteome-wide Binding Propensity Estimation. Computational and Structural Biotechnology Journal, 35(1). https://doi.org/10.34133/csbj.0034
Vancouver
Tashchilova A, Khokhlov I, Seikin A, Bugaev-Makarovskiy N, Glushkova O, Yudin V, et al. DrugForm-TAS: Target-Agnostic Selectivity as Proteome-wide Binding Propensity Estimation. Computational and Structural Biotechnology Journal. 2026;35(1). doi:10.34133/csbj.0034
BibTeX
@article{Tashchilova2026,
author = {Tashchilova, Anna and Khokhlov, Ivan and Seikin, Alexey and Bugaev-Makarovskiy, Nickolay and Glushkova, Olga and Yudin, Vladimir and Keskinov, Anton and Yudin, Sergey and Svetlichnyy, Dmitry and Skvortsova, Veronika},
title = {DrugForm-TAS: Target-Agnostic Selectivity as Proteome-wide Binding Propensity Estimation},
journal = {Computational and Structural Biotechnology Journal},
year = {2026},
volume = {35},
number = {1},
doi = {10.34133/csbj.0034}
}
EUVIMED